SMTL ID : 8tu4.1

Bruton's tyrosine kinase in complex with covalent inhibitor compound 25

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.60 Å

Oligo State

monomer

Ligands

1 x V72: N-methyl-N-[(1S,3r)-3-methyl-3-{[(6M,8S)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy}cyclobutyl]propanamide

V72.1: 14 residues within 4Å: Chain A: L.32, G.33, T.34, V.40, A.52, E.99, Y.100, M.101, A.102, G.104, C.105, N.108, R.149, L.152 6 PLIP interactions: 6 interactions with chain A Hydrophobic interactions: A:L.32, A:A.52, A:L.152 Hydrogen bonds: A:M.101, A:N.108 Water bridges: A:C.105

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Himmelbauer, M.K. et al., Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis. J.Med.Chem. (2024)

Release Date

2024-06-26

Peptides

Tyrosine-protein kinase BTK: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Tyrosine-protein kinase BTK

Related Entries With Identical Sequence